2012;76(10): 2289-2304. 43. Ganesan AN, Chew DP, Hartshorne T, et al. The impact of atrial brillation type on the risk of thromboembolism, mortality, and bleeding: a systematic review and meta-analysis. Eur Heart J. 2016;37(20):1591-1602. 44. Wasywich CA, Pope AJ, Somaratne J, Poppe KK, Whalley GA, Doughty RN. Atrial brillation and the risk of death in patients with heart failure: a literature-based meta-analysis. Intern Med J. 2010;40(5):347-356. 45. Melgaard L, Gorst-Rasmussen A, Lane DA, Rasmussen LH, Larsen TB, Lip GY. Assessment of the CHA2DS2-VASc score in predicting ischemic stroke, thromboembolism, and death in patients with heart failure with and without atrial brillation. JAMA. 2015;314(10):1030-1038. 46. Ling LH, Kistler PM, Kalman JM, Schilling RJ, Hunter RJ. Comorbidity of atrial brillation and heart failure. Nat Rev Cardiol. 2016;13(3):131-147. 47. P ster R, Bragelmann J, Michels G, Wareham NJ, Luben R, Khaw KT. Performance of the CHARGE-AF risk model for incident atrial brillation in the EPIC Norfolk cohort. Eur J Prev Cardiol. 2015;22(7):932-939. 48. Kotecha D, Chudasama R, Lane DA, Kirchhof P, Lip GY. Atrial brillation and heart failure due to reduced versus preserved ejection fraction: a systematic review and meta-analysis of death and adverse outcomes. Int J Cardiol. 2016;203:660-666. 49. Zeng WT, Sun XT, Tang K, et al. Risk of thromboembolic events in atrial brillation with chronic kidney disease. Stroke. 2015;46(1): 157-163. 50. Olesen JB, Lip GY, Kamper AL, et al. Stroke and bleeding in atrial brillation with chronic kidney disease. N Engl J Med. 2012;367(7): 625-635. 51. Odutayo A, Wong CX, Hsiao AJ, Hopewell S, Altman DG, Emdin CA. Atrial brillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis. BMJ. 2016;354:i4482. 52. Ando G, Capranzano P. Non-vitamin K antagonist oral anticoagulants in atrial brillation patients with chronic kidney disease: a systematic review and network meta-analysis. 